<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080468</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-029</org_study_id>
    <nct_id>NCT02080468</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effect of ethinyl estradiol
      (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK)
      of lomitapide and 2 primary metabolites, M1 and M3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single center, randomized, open-label, 2 arm study to evaluate the
      effects of EE/norgestimate, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy
      female subjects when EE/norgestimate is administered simultaneously with lomitapide and when
      administration is separated by 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2014</start_date>
  <completion_date type="Actual">April 24, 2014</completion_date>
  <primary_completion_date type="Actual">April 24, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Time to reach maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Area under the concentration-time curve from zero to infinity of lomitapide and its metabolites, M1 &amp; M3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
    <description>Apparent terminal elimination half-life of lomitapide and its metabolites, M1 &amp; M3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1: Lomitapide &amp; EE/Norgestimate - Taken Together</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lomitapide &amp; EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lomitapide &amp; EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <description>20 mg</description>
    <arm_group_label>Arm 1: Lomitapide &amp; EE/Norgestimate - Taken Together</arm_group_label>
    <arm_group_label>Arm 2: Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</arm_group_label>
    <other_name>Juxtapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE/norgestimate</intervention_name>
    <description>1x0.035-mg EE/0.25-mg norgestimate tablet</description>
    <arm_group_label>Arm 1: Lomitapide &amp; EE/Norgestimate - Taken Together</arm_group_label>
    <arm_group_label>Arm 2: Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</arm_group_label>
    <other_name>Ortho Cylclen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy females, between 18 and 40 years of age inclusive

          2. BMI between 18.5 and 30.0 kg/m2, inclusive; total body weight of &gt;110 lbs (50 kg);

          3. in good health, determined by no clinically significant or relevant abnormalities
             identified by a detailed medical history and physical exam

          4. no known history of hypersensitivity or previous intolerance to lomitapide or
             EE/norgestimate

          5. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit of
             normal

          6. clinical laboratory evaluations within the reference range for the test laboratory

          7. negative test for selected drugs of abuse

          8. negative hepatitis panel and negative HIV antibody screens

          9. are of childbearing potential(ie, not postmenopausal or surgically sterile). All
             subjects must have a negative serum beta pregnancy test.

         10. able to comprehend and willing to sign an Informed Consent Form

        Exclusion Criteria:

          1. significant history or clinical manifestation of any metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,
             neurological, or psychiatric disorder

          2. history of unexplained breast abnormalities or abnormal uterine bleeding

          3. history of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance

          4. history of stomach or intestinal surgery or resection

          5. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome

          6. subjects who have an abnormality in the 12-lead ECG

          7. use of any drugs of abuse for 6 months prior to Check-in;

          8. subjects who consume more than 14 units of alcohol per week or who have a significant
             history of alcoholism or drug/chemical abuse within 1 year prior to Check-in

          9. use of any tobacco- or nicotine-containing products within 6 months prior to Check-in;

         10. participation in any other investigational study drug trial within 30 days prior to
             Check-in;

         11. use of any prescription medications/products within 14 days prior to Check-in unless
             deemed acceptable by the Investigator and Sponsor

         12. use of any over-the-counter, nonprescription preparations within 7 days prior to
             Check-in, unless deemed acceptable by the Investigator and Sponsor

         13. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or
             beverages within 72 hours prior to Check-in and through Study Completion

         14. use of oral (except scheduled administration of EE/norgestimate), implantable,
             injectable, or transdermal contraceptives

         15. use of hormone replacement therapy

         16. poor peripheral venous access;

         17. donation of blood (500 mL) from 30 days prior to Screening through Study Completion

         18. receipt of blood products within 2 months prior to Check-in;

         19. any acute or chronic condition, scheduled hospitalization (inclusive of elective
             surgery during study) or scheduled travel prior to completion of all study procedures
             which, in the opinion of the Investigator, would limit the subject's ability to
             complete and/or participate in this clinical study;

         20. subjects who, in the opinion of the Investigator, should not participate in this
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sumeray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cheif Medical Officer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Alex King, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effect</keyword>
  <keyword>Ethinyl Estradiol/Norgestimate</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Lomitapide.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norgestimate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lomitapide &amp; EE/Norgestimate - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 8 through day 28)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
        <group group_id="P2">
          <title>Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 9 through day 29)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lomitapide &amp; EE/Norgestimate - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 8 through day 28)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
        <group group_id="B2">
          <title>Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 9 through day 29)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="6.4"/>
                    <measurement group_id="B2" value="29" spread="5.7"/>
                    <measurement group_id="B3" value="29" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
        <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
          <description>Maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="39.1"/>
                    <measurement group_id="O2" value="1.39" spread="58.4"/>
                    <measurement group_id="O3" value="2.96" spread="27.0"/>
                    <measurement group_id="O4" value="2.95" spread="19.4"/>
                    <measurement group_id="O5" value="36.3" spread="32.1"/>
                    <measurement group_id="O6" value="34.0" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
        <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
          <description>Time to reach maximum observed plasma concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="5.00" lower_limit="1.00" upper_limit="18.0"/>
                    <measurement group_id="O3" value="8.28" lower_limit="5.00" upper_limit="12.0"/>
                    <measurement group_id="O4" value="6.00" lower_limit="2.00" upper_limit="12.0"/>
                    <measurement group_id="O5" value="5.02" lower_limit="3.00" upper_limit="12.0"/>
                    <measurement group_id="O6" value="3.97" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
        <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
          <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="35.0"/>
                    <measurement group_id="O2" value="42.7" spread="49.5"/>
                    <measurement group_id="O3" value="89.3" spread="35.6"/>
                    <measurement group_id="O4" value="96.8" spread="32.1"/>
                    <measurement group_id="O5" value="456" spread="41.2"/>
                    <measurement group_id="O6" value="371" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
        <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
          <description>Area under the concentration-time curve from zero to infinity of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="34.8"/>
                    <measurement group_id="O2" value="46.5" spread="49.1"/>
                    <measurement group_id="O3" value="91.4" spread="35.8"/>
                    <measurement group_id="O4" value="99.4" spread="32.4"/>
                    <measurement group_id="O5" value="463" spread="40.9"/>
                    <measurement group_id="O6" value="377" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
        <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Coadministered Simultaneously)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered Simultaneously)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered Simultaneously)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate simultaneously</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Arm 1 (Lomitapide &amp; EE/Noregestimate - Taken Together)</title>
          <description>Apparent terminal elimination half-life of lomitapide and its 2 primary metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="16.1"/>
                    <measurement group_id="O2" value="53.6" spread="19.0"/>
                    <measurement group_id="O3" value="32.5" spread="20.3"/>
                    <measurement group_id="O4" value="36.8" spread="30.3"/>
                    <measurement group_id="O5" value="38.3" spread="32.7"/>
                    <measurement group_id="O6" value="39.8" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
        <description>Maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Codministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
          <description>Maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="50.7"/>
                    <measurement group_id="O2" value="1.39" spread="56.5"/>
                    <measurement group_id="O3" value="2.87" spread="20.6"/>
                    <measurement group_id="O4" value="3.04" spread="22.8"/>
                    <measurement group_id="O5" value="37.8" spread="26.2"/>
                    <measurement group_id="O6" value="33.0" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
        <description>Time to reach maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Codministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
          <description>Time to reach maximum observed plasma concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="5.00" upper_limit="10.0"/>
                    <measurement group_id="O2" value="8.00" lower_limit="3.00" upper_limit="11.8"/>
                    <measurement group_id="O3" value="9.07" lower_limit="5.00" upper_limit="12.0"/>
                    <measurement group_id="O4" value="8.00" lower_limit="3.00" upper_limit="11.9"/>
                    <measurement group_id="O5" value="6.00" lower_limit="5.00" upper_limit="10.0"/>
                    <measurement group_id="O6" value="5.50" lower_limit="2.00" upper_limit="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
        <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Codministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
          <description>Area under the concentration-time curve from zero to last quantifiable concentration of lomitapide and its metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="49.9"/>
                    <measurement group_id="O2" value="46.5" spread="55.1"/>
                    <measurement group_id="O3" value="92.3" spread="31.1"/>
                    <measurement group_id="O4" value="93.7" spread="34.2"/>
                    <measurement group_id="O5" value="520" spread="30.1"/>
                    <measurement group_id="O6" value="377" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
        <description>Area under the concentration-time curve from zero to infinity of lomitapide and its metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Codministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
          <description>Area under the concentration-time curve from zero to infinity of lomitapide and its metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="50.9"/>
                    <measurement group_id="O2" value="51.2" spread="55.3"/>
                    <measurement group_id="O3" value="94.5" spread="31.3"/>
                    <measurement group_id="O4" value="96.4" spread="34.6"/>
                    <measurement group_id="O5" value="528" spread="30.0"/>
                    <measurement group_id="O6" value="383" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
        <description>Apparent terminal elimination half-life of lomitapide and its metabolites, M1 &amp; M3.</description>
        <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing</time_frame>
        <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PK of Lomitapide (Lomitapide Alone)</title>
            <description>PK of lomitapide following administration of lomitapide alone</description>
          </group>
          <group group_id="O2">
            <title>PK of Lomitapide (Codministered 12 Hours Apart)</title>
            <description>PK of lomitapide following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O3">
            <title>PK of M1 (Lomitapide Alone)</title>
            <description>PK of M1 following administration of lomitapide alone</description>
          </group>
          <group group_id="O4">
            <title>PK of M1 (Coadministered 12 Hours Apart)</title>
            <description>PK of M1 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
          <group group_id="O5">
            <title>PK of M3 (Lomitapide Alone)</title>
            <description>PK of M3 following administration of lomitapide alone</description>
          </group>
          <group group_id="O6">
            <title>PK of M3 (Coadministered 12 Hours Apart)</title>
            <description>PK of M3 following administration of lomitapide coadministered with EE/Norgestimate 12 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Arm 2 (Lomitapide &amp; EE/Noregestimate - 12 Hours Apart)</title>
          <description>Apparent terminal elimination half-life of lomitapide and its metabolites, M1 &amp; M3.</description>
          <population>The Pharmacokinetic Analysis population included all subjects. Only subjects who completed both periods were included in the ANOVA analyses.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="22.2"/>
                    <measurement group_id="O2" value="52.0" spread="16.1"/>
                    <measurement group_id="O3" value="36.2" spread="21.0"/>
                    <measurement group_id="O4" value="37.2" spread="19.1"/>
                    <measurement group_id="O5" value="38.0" spread="28.0"/>
                    <measurement group_id="O6" value="33.6" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lomitapide &amp; EE/Norgestimate - Taken Together</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 8 through day 28)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
        <group group_id="E2">
          <title>Lomitapide &amp; EE/Norgestimate - Taken 12 Hours Apart</title>
          <description>2 single oral doses of lomitapide (20 mg) (Day 1 &amp; Day 22)
21 single oral doses of EE/Norgestimate(Day 9 through day 29)
lomitapide: 20 mg
EE/norgestimate: 1x0.035-mg EE/0.25-mg norgestimate tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Punction Site Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Described in site contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Long, MD - VP Clinical</name_or_title>
      <organization>Aegerion Pharmaceuticals, Inc.</organization>
      <phone>617-500-5142</phone>
      <email>alison.long@aegerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

